Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T21:53:05.397Z.
Calculation as of: 2026-10-06T21:53:05.397Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9e5af3e3eb74887b0741ac42ed15d75d820cdffcd327c1f2ecbbd665592eb47e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Relmada Therapeutics, Inc.
Market Cap
$344.04M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$346.73M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$349.70M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$353.00M
Free Cash Flow Yield
46.63%
TTM Avg
52.29%
3Y Avg
21.98%
5Y Avg
21.35%
Market Cap
$353.88M
Free Cash Flow Yield
N/A
TTM Avg
3.10%
3Y Avg
3.51%
5Y Avg
4.59%
Market Cap
$355.36M
Free Cash Flow Yield
8.23%
TTM Avg
4.35%
3Y Avg
3.49%
5Y Avg
2.60%
Market Cap
$355.43M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$330.19M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Relmada Therapeutics, Inc. (RLMD) | $344.04M | N/A | N/A | N/A | N/A |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | N/A | N/A | N/A | N/A |
| Ocugen, Inc. (OCGN)vs › | $352.67M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $353.00M | 46.63% | 52.29% | 21.98% | 21.35% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | N/A | 3.10% | 3.51% | 4.59% |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 8.23% | 4.35% | 3.49% | 2.60% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | N/A | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $330.19M | N/A | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $329.37M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
